Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III
SNY begins phase III study for its 21-valent pneumococcal conjugate vaccine for treating invasive pneumococcal disease in ...
Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction
Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...
The Korea Times on MSN17 小时
SK Bioscience wins W530 bil. deal for pneumococcal vaccine
SK Bioscience and global pharmaceutical giant Sanofi signed an expanded agreement to jointly develop next-generation ...
GlobalData on MSN9 小时
SK bioscience and Sanofi expand agreement for pneumococcal conjugate vaccines
SK bioscience and Sanofi have expanded their agreement to jointly develop pneumococcal conjugate vaccines (PCVs) targeting ...
Korea Joongang Daily on MSN15 小时
SK bioscience and Sanofi extend partnership to develop next-gen vaccines
SK bioscience and Sanofi, a global healthcare company, extended their partnership to co-develop next-generation pneumococcal ...
The Citizen18 小时
Protect your child against serious diseases
Throughout history, immunisation has helped protect millions of children against infectious and life-threatening diseases. Immunisation helps to strengthen your child’s immune system to fight diseases ...
FierceBiotech10 小时
Sanofi pays SK bioscience €50M as children's pneumococcal vaccine enters phase 3
Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...
Finanznachrichten15 小时
Sanofi: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK ...
This vaccine candidate is the first-ever PCV containing more than 20 serotypes to enter a phase 3 clinical study in infants and toddlers. Thomas Triomphe Executive Vice President, Vaccines, Sanofi ...